Orally supplemented Lactobacillus acidophilus strain L-92 inhibits passive and active cutaneous anaphylaxis as well as 2,4-dinitroflurobenzene and mite fecal antigen induced atopic dermatitis-like skin lesions in mice

Authors

  • Mohammad Monir Shah,

    1. Laboratory of Bioresponses and Regulation, United Graduate School of Drug Discovery and Medical Information Science
    2. Department of Microbiology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1193
    Search for more papers by this author
  • Yoshihiro Miyamoto,

    1. Laboratory of Pharmacology, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu 501-1196, Japan
    Search for more papers by this author
  • Yoshihito Yamada,

    1. Laboratory of Pharmacology, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu 501-1196, Japan
    Search for more papers by this author
  • Hirotaka Yamashita,

    1. Laboratory of Bioresponses and Regulation, United Graduate School of Drug Discovery and Medical Information Science
    2. Laboratory of Pharmacology, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu 501-1196, Japan
    Search for more papers by this author
  • Hiroyuki Tanaka,

    1. Laboratory of Bioresponses and Regulation, United Graduate School of Drug Discovery and Medical Information Science
    2. Laboratory of Pharmacology, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu 501-1196, Japan
    Search for more papers by this author
  • Takayuki Ezaki,

    1. Department of Microbiology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1193
    Search for more papers by this author
  • Hiroichi Nagai,

    1. Laboratory of Pharmacology, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu 501-1196, Japan
    Search for more papers by this author
  • Naoki Inagaki

    1. Laboratory of Bioresponses and Regulation, United Graduate School of Drug Discovery and Medical Information Science
    2. Laboratory of Pharmacology, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu 501-1196, Japan
    Search for more papers by this author

Correspondence
Naoki Inagaki, Laboratory of Bioresponses and Regulation, United Graduate School of Drug Discovery and Medical Information Science, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan. Tel: and fax: +81 58 230 8123; email: inagakin@gifu-pu.ac.jp

ABSTRACT

Oral supplementation of lactic acid bacteria is a potential approach to the prevention and manipulation of allergic diseases such as atopic dermatitis. Our previous report showed that heat-killed Lactobacillus acidophilus strain L-92 (L-92) possessed anti-allergic properties, although its physiological function in atopic dermatitis has largely remained undefined. To evaluate the anti-allergic efficacy of L-92, we used four experimental animal models with the major features of atopic dermatitis and compared the results to those of clinically active drugs. ICR mice were passively sensitized by anti-dinitrophenyl mouse monoclonal IgE for passive cutaneous anaphylaxis (PCA), and BALB/c mice were actively sensitized by ovalbumin for active cutaneous anaphylaxis (ACA). Allergic reaction was induced by repeated exposure to 2,4-dinitroflurobenzene (DNFB) and mite (Dermatophagoides farinae) fecal allergen, in BALB/c and NC/Nga mice, respectively. Orally administrated L-92 significantly inhibited the vascular permeability increase in both PCA and ACA, and the elevation of ovalbumin-specific IgE titer in ACA. Moreover, repeated applications of DNFB and mite fecal antigen onto the BALB/c and NC/Nga mouse ear, respectively, caused clinical symptoms similar to atopic dermatitis such as ear swelling, scratching behavior and elevation of total serum IgE levels that were also moderately suppressed by L-92. In addition, L-92 treated mice exhibited lower levels of mast cells, eosinophil infiltration and Th1/Th2 cytokine expression. Our results, therefore, suggest that oral administration of L-92 might be useful for alleviating allergic symptoms.

Ancillary